Physician profile
Bruce David Long
NPI 1366427684
$17,988.83
in general payments reported to CMS, 2019-2025
11 companies · $151 in 2025
The $151 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18K · 2023: $241 · 2024: $81.70 · 2025: $151.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $473.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $473.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $12,862.36 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $3,918.60 | 2019 | |
| Mallinckrodt Enterprises LLC | $341.78 | 2019 | |
| Amgen INC. | $232.04 | 2023-2025 | Evenity, Prolia |
| Alexion Pharmaceuticals, INC. | $206.00 | 2019-2023 | Strensiq |
| Genentech USA, INC. | $153.38 | 2019-2023 | Actemra |
| Horizon Therapeutics Plc | $110.38 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.31 | 2025 | |
| Gilead Sciences, INC. | $40.12 | 2023 | Veklury |
| Merck Sharp & Dohme LLC | $27.40 | 2019 | |
| Lilly USA, LLC | $16.46 | 2023 | Taltz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Long listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.